Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
暂无分享,去创建一个
H. Dombret | C. Preudhomme | N. Boissel | M. Cheok | Juliette Lambert | S. Castaigne | F. Gonzales | N. Duployez | T. Boyer | L. Fenwarth | E. Fournier | Elise Fournier | J. Lambert | Fanny Gonzales
[1] F. Appelbaum,et al. A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). , 2020, Blood advances.
[2] N. Potter,et al. Molecular MRD status and outcome after transplantation in NPM1 mutated AML: results from the UK NCRI AML17 study. , 2019, Blood.
[3] H. Dombret,et al. Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia patients treated in the ALFA0701 trial. , 2019, Blood.
[4] H. Deeg,et al. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] H. Kantarjian,et al. Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida) , 2019, Blood.
[6] H. Dombret,et al. Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study , 2019, Cancers.
[7] S. Devlin,et al. CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A , 2019, Journal of Hematology & Oncology.
[8] E. Stein,et al. Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant? , 2019, Haematologica.
[9] I. Bernstein,et al. CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. , 2019, JCO precision oncology.
[10] I. Bernstein,et al. ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial , 2019, Blood Cancer Journal.
[11] E. Estey,et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. , 2019, Blood.
[12] R. Greil,et al. Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] V. Costa,et al. The Multifaceted Role of Annexin A1 in Viral Infections , 2023, Cells.
[14] Stanley W. K. Ng,et al. A Novel Predictor of Response to Gemtuzumab Ozogamicin Therapy in AML Provides Strategies for Sensitization of Leukemia Stem Cells in Individual Patients , 2018, Blood.
[15] R. Walter,et al. Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330 , 2018, Haematologica.
[16] H. Dombret,et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial , 2018, Haematologica.
[17] R. Hills,et al. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Markus G. Manz,et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia , 2018, The New England journal of medicine.
[19] Torsten Haferlach,et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. , 2018, Blood.
[20] R. Hills,et al. No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials. , 2018, Blood.
[21] R. Fanin,et al. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission. , 2017, Leukemia research.
[22] I. Bernstein,et al. Gemtuzumab ozogamicin for acute myeloid leukemia. , 2017, Blood.
[23] I. Bernstein,et al. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Gale,et al. Gemtuzumab ozogamicin in acute myeloid leukemia , 2017, Leukemia.
[25] R. Majeti,et al. Biology and relevance of human acute myeloid leukemia stem cells. , 2017, Blood.
[26] E. Estey,et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. , 2017, Blood.
[27] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[28] J. Cayuela,et al. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] R. Hills,et al. Expression of CD33 is a predictive factor for effect of Gemtuzumab Ozogamicin at different doses in adult acute myeloid leukemia , 2016, Leukemia.
[30] Claude Preudhomme,et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia , 2016, Nature.
[31] A. Hagemeijer,et al. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] A. Krämer,et al. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia , 2016, Blood Cancer Journal.
[33] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[34] R. Hills,et al. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial , 2016, Haematologica.
[35] H. Dombret,et al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. , 2016, Blood.
[36] Yashma Patel,et al. Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.
[37] I. Bernstein,et al. CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] S. Raimondi,et al. Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group , 2015, Clinical Cancer Research.
[39] H. Dombret,et al. HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML , 2015 .
[40] I. Bernstein,et al. Treatment of 11q23/MLL + AML with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531 , 2015 .
[41] R. Hills,et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. , 2015, The Lancet. Oncology.
[42] S. Younkin,et al. Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia. , 2015, Human molecular genetics.
[43] E. Estey,et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] B. Wood,et al. Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation , 2013, Leukemia.
[45] H. Kantarjian,et al. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG‐GO) as front‐line regimen in patients with core binding factor acute myelogenous leukemia , 2014, American journal of hematology.
[46] S. Raimondi,et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] E. Estey,et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. , 2014, The Lancet. Oncology.
[48] J. Cayuela,et al. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin , 2014, Oncotarget.
[49] G. Ehninger,et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia , 2014, Blood Cancer Journal.
[50] David A Bennett,et al. CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility. , 2014, Human molecular genetics.
[51] C. Preudhomme,et al. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse , 2014, American journal of hematology.
[52] E. Estey,et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson , 2014, Leukemia.
[53] Sylvie Chevret,et al. Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial , 2014, Oncotarget.
[54] M. Vignetti,et al. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] D. Campana,et al. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia , 2013, Cancer.
[56] Robert K Hills,et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] Paola Fazi,et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.
[58] R. Larson,et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. , 2013, Blood.
[59] E. Estey,et al. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. , 2013, Frontiers in bioscience.
[60] J. Cayuela,et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. , 2013, Blood.
[61] S. Raimondi,et al. Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy , 2013, Clinical Cancer Research.
[62] C. Craddock,et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] Joshua F. McMichael,et al. The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.
[64] I. Bernstein,et al. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. , 2012, Blood.
[65] H. Dombret,et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.
[66] S. Raimondi,et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia , 2012, Cancer.
[67] H. Dombret,et al. Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50–70‐year old: A phase 1/2 study of the acute leukemia French association , 2012, American journal of hematology.
[68] I. Bernstein,et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. , 2008, Blood.
[69] C. Volteau,et al. Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study , 2011 .
[70] R. Foà,et al. High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation , 2011, Haematologica.
[71] R. Hills,et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] F. Lo‐Coco,et al. Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy , 2011, Expert opinion on biological therapy.
[73] M. Kurokawa,et al. Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin. , 2010, Leukemia research.
[74] J. Herman,et al. Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML) , 2010, American journal of hematology.
[75] Elaine Coustan-Smith,et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. , 2010, The Lancet. Oncology.
[76] M. Vignetti,et al. Randomized trial of two schedules of low‐dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML‐19) , 2010, British journal of haematology.
[77] V. V. D. van der Velden,et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] R. Lewensohn,et al. Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML. , 2009, Experimental hematology.
[79] E. Estey,et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] S Pounds,et al. Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study , 2009, Leukemia.
[81] J. Dick,et al. Stem cell concepts renew cancer research. , 2008, Blood.
[82] K. Inokuchi,et al. Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion , 2008, Leukemia.
[83] I. Bernstein,et al. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] F. Mandelli,et al. Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia , 2007, Haematologica.
[85] I. Bernstein,et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. , 2007, Blood.
[86] J. F. Burrows,et al. CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. , 2007, Blood.
[87] R. Bouabdallah,et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group , 2007, Leukemia.
[88] E. Ball. Pairing SOCS with CD33 , 2006 .
[89] W. Stock,et al. A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. , 2006, Leukemia research.
[90] C. Flamant,et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] R. Ohno,et al. Two Patients with All -trans Retinoic Acid-Resistant Acute Promyelocytic Leukemia Treated Successfully with Gemtuzumab Ozogamicin as a Single Agent , 2005, International journal of hematology.
[92] I. Bernstein,et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence , 2005, Cancer.
[93] I. Bernstein,et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. , 2005, Blood.
[94] T. Naoe,et al. Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells , 2005, Leukemia.
[95] M. Linenberger,et al. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance , 2005, Leukemia.
[96] Jonathan A. Cooper,et al. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. , 2004, Blood.
[97] I. Bernstein,et al. Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-γ1 in acute myeloid leukemia cells , 2004, Leukemia.
[98] F. Mandelli,et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. , 2004, Blood.
[99] A. Rohatiner,et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia , 2003 .
[100] B. Dörken,et al. Induction of apoptosis by enediyne antibiotic calicheamicin ϑII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner , 2003, Oncogene.
[101] N. Osheroff,et al. Activation of the DNA-Dependent Protein Kinase by Drug-Induced and Radiation-Induced DNA Strand Breaks , 2003, Radiation research.
[102] I. Bernstein,et al. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. , 2003, Blood.
[103] E. Erba,et al. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. , 2003, Blood.
[104] O. Hammarsten,et al. Cleavage of cellular DNA by calicheamicin γ1 , 2003 .
[105] O. Hammarsten,et al. Cleavage of cellular DNA by calicheamicin gamma1. , 2003, DNA repair.
[106] N. Villamor,et al. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells , 2003, Leukemia.
[107] E. Estey,et al. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. , 2002, Blood.
[108] Ana-Teresa Maia,et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. , 2002, Blood.
[109] I. Bernstein,et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. , 2002, Bioconjugate chemistry.
[110] Irwin Hollander,et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. , 2002, Bioconjugate chemistry.
[111] H. Kantarjian,et al. Acute myeloid leukemia , 2018, Methods in Molecular Biology.
[112] I. Bernstein,et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. , 2001, Blood.
[113] I. Bernstein,et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[114] X. H. Chen,et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[115] I. Bernstein,et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. , 2001, Blood.
[116] D. McVicar,et al. Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. , 2000, Blood.
[117] M. Baccarani,et al. P‐glycoprotein (PGP), lung resistance‐related protein (LRP) and multidrug resistance‐associated protein (MRP) expression in acute promyelocytic leukaemia , 2000, British journal of haematology.
[118] M. Grever,et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. , 1999, Blood.
[119] I. Bernstein,et al. CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate , 2017 .
[120] C. Buckley,et al. The Myeloid-specific Sialic Acid-binding Receptor, CD33, Associates with the Protein-tyrosine Phosphatases, SHP-1 and SHP-2* , 1999, The Journal of Biological Chemistry.
[121] M. Grever,et al. Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR 1 / P-Glycoprotein , MRP 1 , and LRP in Acute Myeloid Leukemia . A Southwest Oncology Group Study , 1999 .
[122] P. Sonneveld,et al. MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia , 1997, British journal of haematology.
[123] J. Dick,et al. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.
[124] I. Bernstein,et al. Expression of myeloid differentiation antigens in acute nonlymphocytic leukemia: increased concentration of CD33 antigen predicts poor outcome--a report from the Childrens Cancer Study Group. , 1992, Medical and pediatric oncology.
[125] L. Lyne,et al. Sensitivity of fibroblasts derived from ataxia-telangiectasia patients to calicheamicin γ1I , 1990 .
[126] I. Bernstein,et al. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. , 1986, Blood.
[127] I. Bernstein,et al. Expression of normal myeloid-associated antigens by acute leukemia cells. , 1986, Blood.
[128] J. Griffin,et al. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. , 1984, Leukemia research.